A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

Clinical Cancer Research

Volumn 21, Issue 1, 2015, Pages 60-67

  Messersmith, Wells A ^a   Shapiro, Geoffrey I ^b   Cleary, James M ^b   Jimeno, Antonio ^a   Dasari, Arvind ^a   Huang, Bo ^c   Shaik, M Naveed ^c   Cesari, Rossano ^c   Zheng, Xianxian ^c   Reynolds, Jennifer M ^c   English, Patricia A ^c   McLachlan, Karen R ^c   Kern, Kenneth A ^c   LoRusso, Patricia M ^d  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c PFIZER INC   (United States)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PF 3084014; 2-(5,7-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-3-YLAMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE; ENZYME INHIBITOR; SECRETASE; TETRALIN DERIVATIVE; VALINE;

ADULT; ADVANCED CANCER; AGED; ANAPHYLACTIC SHOCK; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; GENE; GENE EXPRESSION; HEADACHE; HES4 GENE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PRURITUS; RASH; SOLID TUMOR; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MIDDLE AGED; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; AMYLOID PRECURSOR PROTEIN SECRETASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME; VALINE;

EID: 84920509474     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0607     Document Type: Article

References (30)

1. Shi I, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82.
2. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52.
3. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106.
4. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, Aster JC, et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol 2006;26:4642-51.
5. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Med 2011;17:1646-51.
6. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-57.
7. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
8. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao Q, Proby CM, et al. Loss-offunction mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 2011;108:17761-66.
9. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33.
10. Wang Z, Li Y, Banerjee S, Sarkar FH. Exploitation of the Notch signaling pathway as a novel target for cancer therapy. Anticancer Res 2008;28:3621-30.
11. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA 2012;109:E2939-48.
12. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 2013;19:1972-80.
13. Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 2013;335:41-51.
14. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749-51.
15. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369:341-50.
16. Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C, et al. EGFR signaling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 2008;10:902-11.
17. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010;9:1618-28.
18. Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiombato A, Paietta E, Racevskis J, et al. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012;7:1565-75.
19. Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, et al. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF- 03084014 in breast cancer models. Clin Cancer Res 2012;18:5008-19.
20. Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, et al. Synergistic effect of the gamma-secretase inhibitor PF-03084014 and docetaxel in breast cancer models. Stem Cells Transl Med 2013;2:233-42.
21. Gounder MM, Schwartz GK. Moving forward one Notch at a time. J Clin Oncol 2012;30:2291-93.
22. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kawak EL, Gibbon DG, et al. Phase I study of R04929097, a gammasecretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 2012;30:2348-53.
23. Krop I, Demuth T, Wen PY, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30:2307-17.
24. Richter S, Bedard PL, Chen EX, Clarke BA, Tran B, Hotte SJ, et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs 2013 May 5 [Epub ahead of print].
25. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2011;29:3529-34.
26. Von Mehren M, Benjamin RS, Bui MM, Casper ES, Conrad EU III, DeLaney TF, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:951-60.
27. Montgomery C, Emory C, Adams S, Cohen J, Pitcher JD, Potter BK, et al. Treatment of extra-abdominal desmoid tumors with chemotherapy. Cancers 2001;3:3394-404.
28. Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17:4082-90.
29. Mace J, Biermann JS, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-79.
30. Carothers AM, Rizvi H, Hasson RM, Heit YI, Davids JS, Bertagnolli MM, et al. Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors. Cancer Res 2012;72:346-55.